低手术风险患者肾下腹主动脉瘤腔内修复与开放手术修复的中期结果比较
单中心2003至2017年收治的低手术风险肾下腹主动脉瘤患者227例,EVAR占59.9%、OR占40.1%,平均随访80±48个月。EVAR组主要不良事件和30天再干预率更低,30天死亡率两组均为0%;5年再干预率和生存率无显著差异。
要点
- 低手术风险肾下腹主动脉瘤患者中,EVAR组主要不良事件发生率2.6%,OR组19.7%(P=.001)。
- EVAR组30天再干预率1.5%,OR组8.8%(P=.016);两组30天死亡率均为0%。
- 5年再干预率EVAR 18.5% vs OR 17.6%(P=.67),生存率EVAR 85% vs OR 91%(P=.195),均无显著差异。
核心结论
- 在低手术风险腹主动脉瘤患者中,EVAR可能提供与OR相当的中期结果,且主要不良事件发生率更低、住院时间更短。
- 作者认为在当前低风险患者OR优先的模式下,决策时应考虑解剖适合性、性功能障碍风险、2型内漏风险和随访需求等因素。
研究设计与样本
- 单中心三级医疗机构的 elective 腹主动脉瘤患者,2003至2017年接受治疗。
- 纳入术前并发症和围手术期死亡低风险(Medicare Aneurysm Scoring System <3)的患者,共227例(EVAR 59.9%,OR 40.1%),平均随访80±48个月。
- 另进行倾向性评分匹配队列分析,平衡年龄、危险因素和合并症。
主要发现
- EVAR组年龄66.6±5岁 vs OR组64.1±6岁(P<.001),BMI 29.6±4 vs 28.1±3 kg/m2(P=.005),慢性阻塞性肺疾病患病率27.3% vs 9.9%(P=.001),血脂异常患病率46.3% vs 65.9%(P=.004)。
- OR组主要不良事件发生率19.7% vs EVAR组2.6%(P=.001),30天再干预率8.8% vs 1.5%(P=.016),两组30天死亡率均为0%。
- 倾向性评分匹配队列包含76对匹配患者(1:1),住院时间和主要并发症差异仍显著,但未影响死亡率。
- 5年随访时,再干预率EVAR 18.5% vs OR 17.6%(P=.67),生存率EVAR 85% vs OR 91%(P=.195),均无显著差异。
临床怎么用
- 作者认为在低手术风险腹主动脉瘤患者中,EVAR可能提供与OR相当的中期结果,且主要不良事件发生率更低、住院时间更短。
- 作者认为在当前低风险患者OR优先的模式下,决策时应考虑解剖适合性、性功能障碍风险、2型内漏风险和随访需求等因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to analyze midterm outcomes of endovascular repair (EVAR) versus open repair (OR) for treatment of infrarenal abdominal aortic aneurysms (AAAs) in low surgical risk patients. METHODS: Elective patients with AAAs undergoing treatment from 2003 to 2017 in a single, tertiary-care institution were evaluated. All patients with a low preoperative risk of complications and perioperative mortality (Medicare Aneurysm Scoring System <3) were included, and rates of perioperative and long-term mortality, adverse events, and reintervention were evaluated for EVAR and OR. A propensity score-matched cohort, leveling age, risk factors, and comorbidities was additionally performed. RESULTS: A total of 227 patients were included (EVAR 59.9% and OR 40.1%) and followed for a mean of 80 ± 48 months. Patients undergoing EVAR were older (66.6 ± 5 vs. 64.1 ± 6 years; P <.001), had a higher body mass index (29.6 ± 4 vs 28.1 ± 3 kg/m2; P = .005), a higher prevalence of chronic obstructive pulmonary disease (27.3% vs 9.9%; P = .001), and lower prevalence of dyslipidaemia (46.3% vs 65.9%; P = .004). Patients undergoing OR had a higher rate of major adverse events (19.7% vs 2.6%; P = .001) and 30-day reinterventions (8.8% vs. 1.5%; P = .016), with 30-day mortality being 0% in both groups. The propensity-score matched cohort included 76 matched pairs (1:1), with differences in hospital stay and major complications remaining significant, without affecting mortality. At 5-year follow-up, there were no significant differences in the reintervention rate (EVAR 18.5% vs OR 17.6%; P = .67) or survival (EVAR 85% vs OR 91%; P = .195). CONCLUSIONS: In low surgical risk patients with AAAs, EVAR may offer comparable midterm results to OR, with a lower rate of major adverse events and a shorter in-hospital stay. With the current OR-first paradigm in low-risk patients, several factors should be taken into account for decision-making (anatomic suitability, risk of sexual dysfunction, risk of type 2 endoleaks, and need for follow-up).
引用
- Arenas Azofra E, Iglesias Iglesias C, Canga Gonzalez C, et al. Midterm results of endovascular versus open surgical repair for infrarenal abdominal aortic aneurysms in low surgical risk patients. J Vasc Surg. 2021. PMID: 34793922. doi:10.1016/j.jvs.2021.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。